Avelumab (Bavencio) as a maintenance treatment after chemotherapy significantly extended overall survival in patients with advanced urothelial cancer, according to findings from thephase III JAVELIN Bladder 100 trial.
Advances in endourology have made kidney-sparing treatments a viable treatment option.
Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
The breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.